Molecular analyses and phylogeny of the herpes simplex virus 2 US9 and glycoproteins gE/gI obtained from infected subjects during the Herpevac Trial for Women

Kelsey L. Rowe¹, Miguel A. Minaya¹, Robert B. Belshe², Lynda A. Morrison¹,²*

¹ Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America, ² Department of Internal Medicine, Division of Infectious Diseases, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America

These authors contributed equally to this work.

lynda.morrison@health.slu.edu

Abstract

Herpes simplex virus 2 (HSV-2) is a large double-stranded DNA virus that causes genital sores when spread by sexual contact and is a principal cause of viral encephalitis in newborns and infants. Viral glycoproteins enable virion entry into and spread between cells, making glycoproteins a prime target for vaccine development. A truncated glycoprotein D2 (gD2) vaccine candidate, recently tested in the phase 3 Herpevac Trial for Women, did not prevent HSV-2 infection in initially seronegative women. Some women who became infected experienced multiple recurrences during the trial. The HSV US7, US8, and US9 genes encode glycoprotein I (gI), glycoprotein E (gE), and the US9 type II membrane protein, respectively. These proteins participate in viral spread across cell junctions and facilitate anterograde transport of virion components in neurons, prompting us to investigate whether sequence variants in these genes could be associated with frequent recurrence. The nucleotide sequences and dN/dS ratios of the US7-US9 region from viral isolates of individuals who experienced multiple recurrences were compared with those who had had a single episode of disease. No consistent polymorphism(s) distinguished the recurrent isolates. In frequently recurring isolates, the dN/dS ratio of US7 was low while greater variation (higher dN/dS ratio) occurred in US8, suggesting conserved function of the former during reactivation. Phylogenetic reconstruction of the US7-US9 region revealed eight strongly supported clusters within the 55 U.S. HSV-2 strains sampled, which were preserved in a second global phylogeny. Thus, although we have demonstrated evolutionary diversity in the US7-US9 complex, we found no molecular evidence of sequence variation in US7-US9 that distinguishes isolates from subjects with frequently recurrent episodes of disease.

Introduction

Herpes simplex virus 2 (HSV-2) is a large, enveloped dsDNA virus with an icosahedral capsid, a dense layer of tegument proteins, and a host cell-derived lipid envelope studded with viral
HSV-2 traditionally causes genital sores when spread by sexual contact, although due to changing sexual practices HSV-1 causes an equivalent proportion of HSV genital infections [2–4]. Because subclinical infections are common, many individuals are unaware that they are infected. Seroprevalence of HSV-2 in 14 to 49-year-olds in the United States between 2005 and 2010 was estimated to be 15.7% [5]. Herpes simplex encephalitis, caused by HSV-2 or HSV-1, is the most common cause of viral encephalitis in infants [6]. Viral shedding of HSV from the maternal genital tract can result in transmission of the virus from mother to child, often leading to encephalitis and multi-organ disseminated disease [4, 7, 8].

During initial infection, HSV initiates cytopathic replication in epithelial cells. Intranuclear inclusions form in infected cells and the infection induces cell-cell fusion to produce multinucleated giant cells. Viral replication causes cell lysis, leading to detachment of the outer epidermis and formation of blisters. HSV then penetrates the dermis and peripheral sensory nerve termini. Retrograde transport of virus through axons of sensory neurons brings virus to the ganglia where it establishes latent infection. From latency the virus can reactivate, at which time virion components are transported anterogradely through the axon and assemble into virus particles at the peripheral nerve ending. Virus crosses from there to epithelial cells where it replicates to cause recurrent lesions and can reestablish latency. Thus, symptomatic episodes can recur throughout an infected individual’s lifetime [9].

The US7, US8, and US9 genes encode glycoprotein I (gI), glycoprotein E (gE), and US9 type II membrane protein, respectively [10–14]. An additional open reading frame in HSV-1, US8A, overlaps the 3’ portion of the US8 gene and the region between US8 and US9 [15]. During recurrent disease episodes, gE and gI form a protein complex (gE/gI) which functions with US9 to facilitate anterograde viral spread through neurons [16, 17], but the mechanism of enhanced transport is not fully understood. One hypothesis proposes gE/gI and US9 promote the accumulation of membrane vesicles containing virion components and enveloped virions in the trans-Golgi network (TGN) of neuronal cell bodies. Virion components in the TGN-like membranes are then likely loaded onto kinesin motors. This makes the role of gE/gI and US9 vital for axonal transport of the virus. [16]. A similar theory, the “missorting model,” proposes that gE/gI and US9 share TGN sorting motifs, with loss of gE/gI or US9 leading to misrouted capsids and enveloped virions that cannot enter axons to be transported [11]. The HSV-1 US8A protein also facilitates neuronal spread of virus particles into the central nervous system (CNS) from peripheral sites [18] but the precise mechanism promoting neuroinvasion is not known. In addition to its role in neuronal transport, the gE/gI complex acts as an Fc receptor (FcRγ). This FcRγ inhibits antiviral IgG activity by attaching to the Fc portion of an antibody molecule specifically bound via its Fab domain to a viral antigen on the virion surface. In this way, antibody bipolar bridging blocks all activities mediated by the IgG, allowing viral evasion [19].

HSV glycoprotein D (gD) mediates specific entry into cells, and has therefore been considered a prime target for vaccine development [20]. However, a truncated glycoprotein D2 (gD2) vaccine candidate recently tested in the phase 3 Herpevac Trial for Women was not successful in preventing HSV-2 infection or disease [21]. Some women who became infected during the trial experienced multiple episodes of recurrent disease, while others did not. To explore this phenotypic variation, we investigated whether amino acid sequence differences in the gE/gI and US9 proteins are associated with more frequent recurrence. Sequences of the corresponding US7, US8 and US9 genes of HSV-2 isolates obtained during the Herpevac Trial from subjects who had a single episode of disease were compared with those who had experienced three or more recurrent disease episodes. We also evaluated selection pressures on these viral genes and the phylogenetic associations among the HSV-2 US7-US9 genes sequenced from the U.S. and from diverse parts of the world.
Materials and methods

Study design and sample collection

In the Herpevac Trial for Women, subjects were vaccinated at months 0, 1, and 6 with either the investigational vaccine, consisting of 20 μg of glycoprotein D2 from HSV-2 strain G in alum and 3-O-deacylated monophosphoryl lipid A as an adjuvant, or a control hepatitis A vaccine. The non-recurrent endpoint was prevention of genital herpes disease caused by HSV-1, HSV-2, or both from month 2 (1 month after dose 2) through month 20 [21, 22]. Swab samples were collected from subjects experiencing either “non-recurrent” or “recurrent” symptomatic disease. Here we define “non-recurrent” isolates as those derived from subjects who experienced a single disease episode during the trial. The “recurrent” isolates were taken from the last disease episode of subjects who had 3 or more recurrences during the trial. A total of 12 non-recurrent and 8 recurrent isolates were obtained from 20 subjects who became infected with HSV-2 during the vaccine trial. The study was approved by the Saint Louis University Institutional Review Board (IRB number 27007). Subjects provided written consent to future use of their samples.

Cells and viruses

Vero cells (African green monkey kidney epithelial origin), were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 3% newborn calf and 3% bovine growth sera, 100 IU/ml penicillin and 0.1 mg/ml streptomycin (1x P/S), and were originally obtained from David Knipe. HSV-2 swab isolates in transport medium collected during the trial were thawed and 100 μl were inoculated onto Vero cell monolayers in 75cm² flasks. Monolayers were incubated until cytopathic effect reached 100%, and cell lysate stocks of the isolates were prepared [23].

DNA isolation and sequencing

Viral DNA was purified from a portion of each virus lysate using QIAmp DNA Mini kit (QIagen, Valencia, CA) according to the manufacturer’s recommendations. Us7, Us8, Us8A and Us9 were PCR-amplified using strain-specific overlapping primers (Table 1). Amplification reactions used a reaction mixture containing 0.75 μl of forward and reverse primer (10 mM),

Table 1. Primers used for amplification of HSV-2 Us7, Us8 and Us9.

| Gene         | Name                | Genome location  | Sequence 5’ to 3’   |
|--------------|---------------------|------------------|---------------------|
| HSV-2 Us7    | Fwd1_US7_HSV2       | 142079           | TCA TCG GCG GTA TTG CGT T |
|              | Rev1_US7_HSV2       |                  | GCC GTT ATA CAC AAA CGT CCC |
| HSV-2 Us7    | Fwd2_US7_HSV2       | 142708           | GCG TTC ACC TTG TGT CGC TC |
|              | Rev2_US7_HSV2       | 143659           | CCC ATC CAT TAC CGG CCT C |
| HSV-2 Us8-Us9| Fwd1_US8-9_HSV2     | 143608           | TGC GTG TGT TGG ATC CCT TT |
|              | Rev1_US8-9_HSV2     | 144457           | GGG ACA CCT CGG GGA TAA CA |
| HSV-2 Us8-Us9| Fwd2_US8-9_HSV2     | 143876           | GTT TGG GTC GTA TGC TCC CT |
|              | Rev2_US8-9_HSV2     | 144661           | GCT GCG GGT GAT ACA GAC AA |
| HSV-2 Us8-Us9| Fwd3_US8-9_HSV2     | 144604           | CGT CTG GAT GCG GTT TGA C |
|              | Rev3_US8-9_HSV2     | 145459           | TTA CCA GAG GAC GGA CCG A |
| HSV-2 Us8-Us9| Fwd4_US8-9_HSV2     | 145377           | ATA GCG AGG GGC GTA AAT CTC |
|              | Rev4_US8-9_HSV2     | 146118           | ATT TAG CGG AGC AGC CAC AC |

*Nucleotide position within the HSV-2 strain HG52 (JN561323) complete genome.

https://doi.org/10.1371/journal.pone.0212877.t001
2.5 μl 10X AccuPrime™ Pfx Reaction Mix (Invitrogen), 2.5 μl Betaine solution (5M) (Sigma), 2 μl MgCl₂ (50mM), 1.5 μl DMSO, 0.5 μl Taq DNA polymerase, 3 μl of template DNA (20–30 ng/μl) in a total reaction vol. of 25 μl. The amplification parameters consisted of an initial denaturing step of 2 min at 95˚C, followed by 39 cycles of 20 sec denaturing at 95˚C, 30 sec annealing at primer-specific temperature of 56˚C, and 3 min extension at 68˚C, followed by a final extension step of 5 min at 68˚C. Sanger sequencing of purified PCR products was conducted by GeneWiz, Inc. (South Plainfield, NJ).

### Sequence analyses

Chromatograms of each sequence were visually inspected for overlapping peaks that could indicate a single nucleotide variation (SNV) comprising a portion of the viral population, but none was found. Complementary strands were assembled and verified using the program Sequencher 4.2.2 (Gene Codes Corporation, Ann Arbor, Michigan, U.S.A). The obtained sequences were aligned and adjusted manually using MEGA (v7.0.14) [24]. Improvement of the nucleotide alignments was performed using amino acid translations and by comparing our sequences with the previously published cDNA from HSV-2 strain HG52 (JN561323), a laboratory HSV-2 strain from Scotland [25], and SD90e (KF781518), a clinical isolate of HSV-2 from South Africa [26] (Table 2). These comparisons were also used to check the genic-intergenic boundaries in the U₇-U₈-U₈A-U₉ complex. These alignments were then used to construct amino acid sequence models of the gE, gI and US9 proteins, and the putative HSV-2 homolog of HSV-1 US8A for each strain sampled so that the SNVs and insertions/deletions (INDELs) observed in different sequences could be easily compared.

### Non-synonymous (dN), and synonymous (dS) substitutions

The frequencies of non-synonymous (dN), and synonymous (dS) substitutions and dN/dS ratios for each of the U₇, U₈, U₈A, and U₉ genes were calculated using the SNAP (Synonymous Non-synonymous Analysis Program) v2.1.1 website [27]. A dN/dS ratio of less than one indicates negative purifying selection, meaning that natural selection suppresses protein changes. A dN/dS ratio of greater than one indicates positive selection. A dN/dS ratio equal to one indicates selection neutrality where non-synonymous substitutions occur at a rate equal to synonymous substitutions [28]. The difference in mean ratios of non-synonymous (dN) to synonymous (dS) evolutionary substitutions in HSV-2 U₇, U₈, U₈A, and U₉ from subjects with non-recurrent vs. recurrent disease isolates were then compared for significance by two-tailed t-tests (p < 0.05).

### Phylogenetic analyses

Two HSV-2 phylogenies were used to evaluate the evolutionary relationships between HSV-2 strains using the concatenated sequence of the U₇-U₈-U₈A-U₉ region. Because the main objective of this research is to evaluate whether sequence differences in the gE/gI and US9 proteins obtained from HSV-2 U.S. isolates are associated with more frequent recurrence, a U.S.-restricted phylogeny was first calculated. This phylogeny encompassed 55 HSV-2 isolates from the U.S. (including the 12 non-recurrent and 8 recurrent isolates sequenced from the Herpevac Trial). Sequences were aligned to the sequence of the South African clinical isolate SD90e, and the ChHV-1 sequence was included as an outgroup (Table 2). Second, a phylogeny was calculated using HSV-2 U₇-U₉ sequences from different parts of the world (Table 2): 55 sequences from the U.S., 12 from Peru, 19 from Northern Europe, 5 South African, 21 Tanzanian, and 10 from other SoutheastAfrican countries. Bayesian Inference (BI), Maximum parsimony (MP) and Maximum Likelihood (ML) based searches (including coding and non-coding positions)
## Table 2. Genomes and accession numbers.

| Virus | Strain | Host     | Anatomical region | Isolate history | Collection year | Country of origin | GenBank accession no. |
|-------|--------|----------|-------------------|-----------------|-----------------|-------------------|----------------------|
| HSV-2 | Sample 06 | Human | Genital | Non-recurrent | 2006 | United States | MH612582 |
| HSV-2 | Sample 10 | Human | Genital | Non-recurrent | 2005 | United States | MH612583 |
| HSV-2 | Sample 14 | Human | Genital | Recurrent | 2004 | United States | MF564035 |
| HSV-2 | Sample 15 | Human | Genital | Non-recurrent | 2004 | United States | MH612584 |
| HSV-2 | Sample 17 | Human | Genital | Non-recurrent | 2007 | United States | MH612585 |
| HSV-2 | Sample 18 | Human | Genital | Non-recurrent | 2006 | United States | MH612586 |
| HSV-2 | Sample 19 | Human | Genital | Recurrent | 2008 | United States | MF564037 |
| HSV-2 | Subject 02 | Human | Genital | Non-recurrent | 2004 | United States | MH612587 |
| HSV-2 | Subject 09 | Human | Genital | Recurrent | 2008 | United States | MH612588 |
| HSV-2 | Subject 16 | Human | Genital | Non-recurrent | 2008 | United States | MH612589 |
| HSV-2 | Subject 18 | Human | Genital | Recurrent | 2004 | United States | MH612590 |
| HSV-2 | Subject 23 | Human | Genital | Non-recurrent | 2008 | United States | MH612591 |
| HSV-2 | Subject 27 | Human | Genital | Non-recurrent | 2005 | United States | MH612592 |
| HSV-2 | Subject 32 | Human | Genital | Recurrent | 2005 | United States | MH612593 |
| HSV-2 | Subject 35 | Human | Genital | Recurrent | 2006 | United States | MH612594 |
| HSV-2 | Subject 39 | Human | Genital | Non-recurrent | 2006 | United States | MH612595 |
| HSV-2 | Subject 40 | Human | Genital | Recurrent | 2008 | United States | MH612596 |
| HSV-2 | Subject 42 | Human | Genital | Non-recurrent | 2005 | United States | MH612597 |
| HSV-2 | Subject 46 | Human | Genital | Recurrent | 2008 | United States | MH612598 |
| HSV-2 | Subject 53 | Human | Genital | Non-recurrent | 2008 | United States | MH612599 |
| HSV-2 | 2003 16029 | Human | Genital | Clinical | 2003 | United States | KX574903 |
| HSV-2 | 2004 20601 | Human | Genital | Clinical | 2004 | United States | KX574904 |
| HSV-2 | 2006 38659 | Human | Genital | Clinical | 2006 | United States | KX574907 |
| HSV-2 | 2006 49895 | Human | Genital | Clinical | 1994 | United States | KX574868 |
| HSV-2 | 2007 50074 | Human | Genital | Clinical | 1995 | United States | KX574869 |
| HSV-2 | 2007 22031 | Human | Genital | Clinical | 2007 | United States | KX574870 |
| HSV-2 | 2007 40807 | Human | Genital | Clinical | 2007 | United States | KX574882 |
| HSV-2 | 2008 7539 | Human | Genital | Clinical | 2008 | United States | KX574887 |
| HSV-2 | 2008 16404 | Human | Genital | Clinical | 2008 | United States | KX574884 |
| HSV-2 | 2008 37744 | Human | Genital | Clinical | 2008 | United States | KX574886 |
| HSV-2 | 2009 1245 | Human | Genital | Clinical | 1994 | United States | KX574888 |
| HSV-2 | 2009 13458 | Human | Genital | Clinical | 1994 | United States | KX574889 |
| HSV-2 | 2009 31735 | Human | Genital | Clinical | 1993 | United States | KX574890 |
| HSV-2 | 2009 33777 | Human | Genital | Clinical | 2009 | United States | KX574891 |
| HSV-2 | 2010 21 | Human | Genital | Clinical | 2009 | United States | KX574895 |
| HSV-2 | 2010 6416 | Human | Genital | Clinical | 2010 | United States | KX574896 |
| HSV-2 | 2011 21400 | Human | Genital | Clinical | 1995 | United States | KX574908 |
| HSV-2 | 2011 21761 | Human | Genital | Clinical | 1998 | United States | KX574897 |
| HSV-2 | 2011 33490 | Human | Genital | Clinical | 2011 | United States | KX574898 |
| HSV-2 | 2012 32825 | Human | Genital | Clinical | 2012 | United States | KX574901 |
| HSV-2 | 89 390 | Human | Presumed Genital | Clinical | 1989 | United States | KR135321 |
| HSV-2 | 7444 1996 25809 | Human | Presumed Genital | Clinical | 1996 | United States | KR135314 |
| HSV-2 | 8937 1999 3336 | Human | Presumed Genital | Clinical | 2003 | United States | KR135298 |
| HSV-2 | 10883 2001 13347 | Human | Presumed Genital | Clinical | 2005 | United States | KR135311 |
| HSV-2 | 44 319857 | Human | Presumed Genital | Clinical | 2007 | United States | KR135310 |
| HSV-2 | 44 419851 | Human | Presumed Genital | Clinical | 2007 | United States | KR135309 |

(Continued)
Table 2. (Continued)

| Virus   | Strain | Host      | Anatomical region | Isolate history                          | Collection year | Country of origin | GenBank accession no. |
|---------|--------|-----------|-------------------|------------------------------------------|-----------------|-------------------|-----------------------|
| HSV-2   | 44 619833 | Human     | Presumed Genital  | Clinical *                                | 2007            | United States     | KR135308              |
| HSV-2   | 9335 2005 576 | Human     | Presumed Genital  | Clinical *                                | 2009            | United States     | KR135312              |
| HSV-2   | 9335 2007 14 | Human     | Presumed Genital  | Clinical *                                | 2011            | United States     | KR135313              |
| HSV-2   | BethesdaP5 | Human     | Presumed Genital  | Clinical **                               | Unknown         | United States     | KR135330              |
| HSV-2   | GSC 56   | Human     | Genital           | Low-passage-number clinical               | Unknown         | United States     | KP334094              |
| HSV-2   | 333      | Human     | Genital           | High-passage-number laboratory            | 1971            | United States     | KP192856              |
| HSV-2   | COH 3818 | Human     | Presumed Genital  | Low-passage-number clinical               | Unknown         | United States     | KP334096              |
| HSV-2   | CtSF     | Human     | Presumed Genital  | Low-passage-number clinical               | Unknown         | United States     | KP334093              |
| HSV-2   | 1192     | Human     | Genital           | Low-passage-number clinical               | Unknown         | United States     | KP334095              |
| HSV-2   | HG52     | Human     | Anal              | High-passage-number laboratory            | Prior to 1971   | Scotland, UK      | JN561332              |
| HSV-2   | HSV2 H1421 | Human     | -                 | -                                         | -               | Finland           | KY922723              |
| HSV-2   | HSV2 H12212 | Human    | -                 | -                                         | -               | Finland           | KY922726              |
| HSV-2   | HSV2 H1227 | Human     | -                 | -                                         | -               | Finland           | KY922721              |
| HSV-2   | HSV2 H1526 | Human     | -                 | -                                         | -               | Finland           | KY922724              |
| HSV-2   | HSV2 H1226 | Human     | -                 | -                                         | -               | Finland           | KY922720              |
| HSV-2   | HSV2 H1229 | Human     | -                 | -                                         | -               | Finland           | KY922722              |
| HSV-2   | 2009 4550 | Human     | -                 | -                                         | 2008            | Kenya             | KX574893              |
| HSV-2   | 2009 4556 | Human     | -                 | -                                         | 2008            | Kenya             | KX574894              |
| HSV-2   | N1       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106422              |
| HSV-2   | N2       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106423              |
| HSV-2   | N3       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106424              |
| HSV-2   | N5       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106426              |
| HSV-2   | N6       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106427              |
| HSV-2   | N7       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106428              |
| HSV-2   | N8       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106429              |
| HSV-2   | N9       | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106430              |
| HSV-2   | N10      | Human     | Genital           | Clinical                                  | Prior to 2007   | Norway            | EU106431              |
| HSV-2   | 2004 4373 | Human     | -                 | -                                         | 2003            | Peru              | KX574861              |
| HSV-2   | 2006 30937 | Human    | -                 | -                                         | 2005            | Peru              | KX574866              |
| HSV-2   | 2006 30839 | Human    | -                 | -                                         | 2005            | Peru              | KX574865              |
| HSV-2   | 2006 45028 | Human    | -                 | -                                         | 2005            | Peru              | KX574867              |
| HSV-2   | 2007 38205 | Human    | -                 | -                                         | 2004            | Peru              | KX574860              |
| HSV-2   | 2007 38249 | Human    | -                 | -                                         | 2004            | Peru              | KX574872              |
| HSV-2   | 2007 38606 | Human    | -                 | -                                         | 2004            | Peru              | KX574873              |
| HSV-2   | 2007 38627 | Human    | -                 | -                                         | 2004            | Peru              | KX574874              |
| HSV-2   | 2007 38807 | Human    | -                 | -                                         | 2005            | Peru              | KX574875              |
| HSV-2   | 2007 38901 | Human    | -                 | -                                         | 2007            | Peru              | KX574876              |
| HSV-2   | 2007 38910 | Human    | -                 | -                                         | 2006            | Peru              | KX574877              |
| HSV-2   | 2007 39303 | Human    | -                 | -                                         | 2007            | Peru              | KX574878              |
| HSV-2   | 2007 39521 | Human    | -                 | -                                         | 2005            | South Africa      | KX574879              |
| HSV-2   | SD90e    | Human     | Genital           | Low-passage-number clinical               | 1994            | South Africa      | KP781518              |
| HSV-2   | 2007 39712 | Human    | -                 | -                                         | 2006            | South Africa      | KX574880              |
| HSV-2   | 2007 39729 | Human    | -                 | -                                         | 2007            | South Africa      | KX574881              |
| HSV-2   | 2009 3532 | Human     | -                 | -                                         | 2007            | South Africa      | KX574892              |
| HSV-2   | S 93 4530 | Human     | Genital           | Clinical                                  | Prior to 2007   | Sweden            | EU106468              |
| HSV-2   | S 97 1643 | Human     | Genital           | Clinical                                  | Prior to 2007   | Sweden            | EU106466              |
| HSV-2   | S B4327  | Human     | Genital           | Clinical                                  | Prior to 2007   | Sweden            | EU106469              |

(Continued)
were performed for both the independent and the combined data sets using, respectively, MrBayes 3.2.6 [29, 30], PAUP* 4.0 beta10 [31], and PhyML 3.0 [32]. All gaps were treated as missing data. Tests of goodness of fit for alternative nucleotide substitution models were performed in jModelTest 2 using the Akaike information criterion (AIC) [33], Bayesian Information Criterion (BIC) [34] and a decision-theoretic (DT) performance-based approach [35–37]. jModelTest 2 selected TPM1uf+I as the optimal model. The closest GTR+G model was imposed in the respective partitions for the BI and ML inferences. BI analyses were run with one million generations using the Monte Carlo Markov Chain (MCMC) algorithm. Trees were sampled every 1,000 generations, and 25% of the generations were discarded as burn-in once stability in the likelihood values was attained. A half-compatible consensus Bayesian tree was computed from the 750 posterior probability saved trees. ML analysis was computed using

### Table 2. (Continued)

| Virus | Strain | Host | Anatomical region | Isolate history | Collection year | Country of origin | GenBank accession no. |
|-------|--------|------|-------------------|-----------------|-----------------|-------------------|----------------------|
| HSV-2 | 2009 409 | Human | - | - | 2006 | Tanzania | KX574902 |
| HSV-2 | T 1855 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106440 |
| HSV-2 | T 2032 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106439 |
| HSV-2 | T 2302 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106432 |
| HSV-2 | T 2557 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106436 |
| HSV-2 | T 2737 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106438 |
| HSV-2 | T 3034 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106433 |
| HSV-2 | T 3041 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106441 |
| HSV-2 | T 3111 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106434 |
| HSV-2 | T 4587 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106435 |
| HSV-2 | T 2228 01 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106443 |
| HSV-2 | T 2316 10 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106444 |
| HSV-2 | T 2346 14 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106445 |
| HSV-2 | T 28 2595 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106447 |
| HSV-2 | T 35 2769 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106448 |
| HSV-2 | T 43 742 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106450 |
| HSV-2 | T 47 2929 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106452 |
| HSV-2 | T 53 1390 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106454 |
| HSV-2 | T 56 3127 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106455 |
| HSV-2 | T 70 3486 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106456 |
| HSV-2 | T NN1 | Human | Genital | Clinical | Prior to 2007 | Tanzania | EU106458 |
| HSV-2 | 2011 34727 | Human | - | - | 2011 | Uganda | KX574899 |
| HSV-2 | 2012 9333 | Human | - | - | 2011 | Uganda | KX574906 |
| HSV-2 | 2006 19390 | Human | - | - | 2005 | Zambia | KX574862 |
| HSV-2 | 2006 29060 | Human | - | - | 2005 | Zambia | KX574864 |
| HSV-2 | 2007 8222 | Human | - | - | 2006 | Zambia | KX574883 |
| HSV-2 | 2009 2198 | Human | - | - | 2006 | Zambia | KX574905 |
| HSV-2 | 3006 21832 | Human | - | - | 2005 | Zimbabwe | KX574863 |
| HSV-2 | 2007 38120 | Human | - | - | 2004 | Zimbabwe | KX574871 |
| ChHV-1 | 105640 | Chimpanzee | Oral | Clinical | 2004 | United States | NC023677 |

Underlined GenBank accession numbers were sequenced in this research.
- No information was provided in the source document.
* Isolates underwent two passages on Vero cells.
** This isolate underwent four passages on human diploid fibroblasts.

https://doi.org/10.1371/journal.pone.0212877.t002
20 starting trees from 20 distinct randomized MP trees and 1000 bootstrap (BS) replicates for analysis of U.S. strains. MP analysis was based on heuristic searches of 10,000 random-order-entry trees, with TBR branch swapping and saving no more than 10 trees per replicate. The most parsimonious trees were used to compute the respective strict consensus trees. Branch support was estimated through 1,000 bootstrap replicates [38] using the TBR-M (Tree Bisection Reconstruction swapping, MULPARS OFF) strategy of DeBry [39] as a method to reduce computational time. Clusters were considered strongly supported when at least two out of the three supporting methods tested indicated elevated support: Bayesian Posterior Probabilities (≥80%); Maximum-Parsimony Bootstrap (≥65%); and Maximum-Likelihood Bootstrap (≥65%).

The phylogenetic analyses were also used to identify \(U_7, U_8, U_8A,\) and \(U_9\) SNVs shared within and between different HSV-2 U.S. clusters. SNVs were identified by ordering the nucleotide (3,768 genic and intergenic nucleotide positions) and amino acid sequences [US7 (gI), 1131 nucleotides/377 amino acids; US8 (gE), 1647/549; US8A, 441/147; US9, 270/90] of each strain sampled according to the phylogenetic tree and conducting a detailed visual examination of the concatenated sequences.

**Results**

**Sample selection and vaccination**

Twelve subjects were identified who became infected with HSV-2 and had a single disease episode during the Herpevac Trial; here we define isolates from these subjects as “non-recurrent.” Eight subjects had 3 to 7 recurrences during the Trial. We sequenced isolates from the last disease episode of these subjects who had 3 or more recurrences during the trial and define these as “recurrent.” Among the subjects with multiple recurrent disease episodes, the 4 subjects who received the control hepatitis A vaccine (HAV) had an average of 4.75 recurrent episodes of disease, while the 4 who received the investigational HSV vaccine had an average of 3.75 recurrent episodes of disease (\(p > 0.05\)). The average number of days between recurrent disease episodes was 38.8 for HAV vaccine recipients, compared with an average of 54.4 days for those who received the HSV vaccine (\(p > 0.05\)).

**Sequence analyses**

First, polymorphisms in \(Us7-Us9\) among non-recurrent isolates and recurrent isolates were identified by comparison of the nucleotide sequences to the HSV-2 HG52 strain as reference. Aligned sequences were translated and isolates that had the same pattern of amino acid polymorphisms were grouped together. These groups were then classified as consisting of non-recurrent isolates only, recurrent isolates only, or both non-recurrent and recurrent isolates (Fig 1A–1C). In gI, both non-recurrent and recurrent isolates contained V23A, R159L, P215S, 234PA, and I243R. An additional 232PAPA was found in one recurrent isolate. Polymorphisms I11M, A185G, A191V, P192S, I243K, and C282S were unique to gI of non-recurrent isolates, although I11M and V23A fell within the proposed signal peptide (15). No gI polymorphisms were unique to recurrent isolates (Fig 1A). In gE, polymorphisms 44GPE, P194A, M371I, H407P, and P544S occurred in both non-recurrent and recurrent isolates, while E151K, and R524H were found only in non-recurrent isolates. No gE polymorphisms were unique to recurrent isolates (Fig 1B). The HSV-2 \(Us7-Us9\) complex contains another open reading frame homologous to \(Us8A\) of HSV-1. The only identified polymorphism within the translated \(Us8A\) open reading frame, A26T, was found in non-recurrent (subject 2) and recurrent (subject 32) isolates. In US9, polymorphisms P5S was found in both non-recurrent and

---

**Molecular analyses and phylogeny of the HSV-2 gE/gI complex and US9**

---
Molecular analyses and phylogeny of the HSV-2 gE/gI complex and US9
recurrent isolates while D7N, L87V and L88R were found only in non-recurrent isolates. No US9 polymorphisms were unique to recurrent isolates (Fig 1C).

**Non-synonymous (dN), and synonymous (dS) substitutions**

The frequencies of non-synonymous (dN), and synonymous (dS) substitutions were calculated based on the codon-aligned nucleotide sequences in a data set that included the 12 non-recurrent and 8 recurrent isolates, and then dN/dS ratios were determined (Fig 2). The dN/dS ratio for Us7 was significantly higher in non-recurrent isolates compared to frequently recurring subjects’ isolates, with average dN/dS ratios of 2.37 and 0.98 respectively (p = 0.001). Like Us7, Us8A had a significantly higher dN/dS ratio in non-recurrent isolates than recurrent isolates, with an average dN/dS ratio of 0.38 for non-recurrent isolates and 0.02 for recurrent isolates (p = 0.013), although Us8A ratios for both sets of isolates were substantially <1. The dN/dS ratios for Us9 of non-recurrent and recurrent isolates were also both substantially <1 but not significantly different. Conversely, the dN/dS ratio of Us8 was significantly lower in non-recurrent isolates than frequently recurring subjects’ isolates, with average dN/dS ratios of 1.59 and 2.74 respectively (p = 0.019). Notably, both dN/dS ratios for Us8 were >1.

**Phylogenetic reconstruction and nucleotide variations shared between non-related strains**

The 20 HSV-2 sequences obtained in this study provided an additional dataset for assessing the phylogenetic patterns among U.S. HSV-2 strains. The concatenated Us7, Us8, Us8A, and Us9 sequences from a total of 55 strains plus the HG52 and 333 laboratory strains (Table 2) were aligned to SD90e and analyzed using ChHV-1 as an outgroup. The phylogenetic reconstruction revealed 8 well-supported clusters (Fig 3 and S1 Fig). Detailed examination of the sequences revealed six nucleotide variations shared between non-related strains (S1 Fig), four of which were non-synonymous and two synonymous (S1 Fig). Interestingly, non-synonymous nucleotide variations in positions 728 and 729 of Us7 generated three different amino acids in position 243 (isoleucine, serine and lysine; Fig 3). No crystal structure models of homologs for these HSV proteins exist so the biological significance of the polymorphisms, if any, is unclear. Next, the 55 U.S. strains were incorporated into a broader phylogenetic analysis of HSV-2 Us7-Us9 sequences from a total of 121 strains from different parts of the world. The global phylogenetic reconstruction (including strains from South America, North Europe, and Southeast Africa; Table 2 and S2 Fig) revealed the same eight strongly supported clusters, several of which had expanded to include more isolates. In addition, five new small but strongly supported clusters appeared.

**Discussion**

A powerful aspect of this study is that participants in the Herpevac Trial for Women were HSV-1/2 seronegative at outset and had periodic serum samples drawn so their first episode of disease is well documented. Thus, “non-recurrent” individuals could be clearly defined and
distinguished from individuals having multiple disease episodes. Our analysis of 20 HSV-2 isolates from the Herpevac Trial did not reveal a nucleotide or amino acid variant that tracked with frequent recurrence. However, differences in the $d_N/d_S$ ratios of non-recurrent and recurrent isolates were found, suggesting that certain selection pressures act on each protein. The average $d_N/d_S$ ratio for Us7 (gI) and Us9 were significantly higher in non-recurring isolates than the average for the frequently recurring isolates. These results suggest gI and US9 amino acid sequences trend toward a consensus sequence in infected individuals who have frequent disease episodes. Conversely, Us8 (gE)’s $d_N/d_S$ ratio was significantly higher in recurrent (2.74) than non-recurrent (1.59) isolates, and both were $>1$, suggesting that variation in gE confers an advantage to the virus, particularly over time in infected persons. Our sample size was relatively small; possibly a larger dataset would reveal a consistent variation that differentiates frequently recurring viruses. The average $d_N/d_S$ ratios of Us8A from non-recurrent and recurrent isolates were both close to zero, supporting a proposed role of its putative gene product, by analogy to HSV-1 US8A, in invasion of the CNS from peripheral sites [18]. The capacity to reach the nervous system to establish latency is a critical part of the virus’ life cycle. Thus, HSV-2 US8A deserves further study.

**Fig 2.** Mean ratios of non-synonymous ($d_N$) to synonymous ($d_S$) evolutionary substitutions in Us7, Us8, Us8A, and Us9 genes from subjects with non-recurrent vs. recurrent HSV-2 infections. Bars represent the mean ± SEM of 12 non-recurrent or 8 recurrent samples. P values are shown above the bars. ns, not statistically significant.

https://doi.org/10.1371/journal.pone.0212877.g002
If SNVs accumulate with repeated reactivations of HSV-2 from a latent state, sequences from recurrent strains should contain nucleotide variations not present in non-recurrent sequences. This phenomenon would result in sequence convergence, and recurrent sequences might also appear grouped in phylogenetic trees. We did not observe this pattern in the samples and genes studied.

Variation, however, was not uniform across the open reading frames studied. Importantly, we observed that functional domains in gE/gI and US9 are more conserved than other regions of the sequences (Fig 1). gI and gE must form a heterodimer to facilitate anterograde transport of viral glycoproteins and capsids to axon termini during a reactivation [40]. We found no amino acid changes in gI’s proposed domain of interaction with gE (amino acids 129–145) or gE’s proposed domain of interaction with gI (amino acids 231–260), supporting previous findings that the formation of this heterodimer is an essential event. Axonal transport of capsids and glycoproteins is known to be impaired in US9 null mutants [40], and in fact, no amino acid changes in gI or gE were observed at the positions of interaction domains.

Role of sequence variation in virus recurrence

Fig 3. Phylogenetic reconstruction and amino acid variants shared among different U.S. HSV-2 clusters. Amino acid sequences in the SD90e reference strain correspond to gI (highlighted in green), gE (yellow), US8A (orange) and US9 (grey). Each gene segment is also bracketed at the bottom of the figure. Amino acid sequences were ordered according to the Bayesian tree diagrammed on the left side of the figure. Blue and red accession numbers represent, respectively, non-recurrent and recurrent isolates (Table 2). Selected regions with amino acid variation are shown. The position of each amino acid variant shared by non-related clusters (♦) or at which multiple amino acid variants occur (♦) is indicated above the reference strain. Bayesian posterior probabilities (≥80%) and maximum-parsimony bootstrap (≥65%) / maximum-likelihood bootstrap (≥65%) values appear above and below the branches, respectively. ♦ High-passage laboratory strain.

https://doi.org/10.1371/journal.pone.0212877.g003
acid changes occurred in HSV-2 US9 sequences with homology to the proposed kinesin-1 binding domain of HSV-1 US9 (amino acids 55–59) [41]. These findings support vital roles for gI, gE, and US9 in neuronal transport.

**Immune escape**

Comparison of our HSV-2 sequences to the previously described HSV-1 Fc binding domains of gE and gI [19] demonstrated they have similarly located binding domains of identical sequence (Fig 1A and 1B). The absence of polymorphisms in HSV-2 gE’s domain homologous to the mammalian FcRγ (amino acids 318–355) and gI’s domain required for IgG binding (amino acids 128–145) supports previous findings [19], and suggests that the HSV-2 gE/gI as an FcRγ helps maintain viral fitness. T cell recognition of HSV-infected cells is also a critical component of the immune response. A previously identified CTL epitope (restricted by HLA B*5701) occurs in HSV-2 gE at amino acid positions 518–526 [17]. Alteration of the epitope could favor immune escape and thus successful recurrence in HLA B*5701+ individuals. Interestingly, subjects 2 and 27, who did not have recurrent disease, showed variation at gE amino acid position 524. We also observed a variant at position 524 in a previously sequenced isolate of unknown recurrence status, isolate 44_419851 (40). Variation in the HSV-2 gE 518–526 region in non-recurrent isolates could be explained if subjects 2 and 27 had acquired a virus with the gE epitope variant, but they lack the HLAB*5701 allele. Under these circumstances the effect of the variant would be neutral. The high dN/dS ratio findings for Us8 (gE) of recurrent isolates also supports the contention that portions of gE may serve as targets of immune recognition and variation in this protein may confer an evolutionary advantage. It must be borne in mind, however, that evasion of one CTL epitope does not constitute escape from the whole immune arsenal.

**Phylogenetic reconstruction**

Both phylogenetic reconstructions using the 20 study samples and 25 additional U.S. sequences or 101 additional geographically diverse sequences downloaded from GenBank revealed eight well-supported clusters of the concatenated Us7-Us9 region (Fig 3 and S1 and S2 Figs). In contrast to previous studies that focused on nearly complete HSV-2 genomes [42–44], we assessed the phylogenetic relationships among specifically the Us7-Us9 glycoprotein region, including coding and non-coding positions. Two salient observations arose: First, we did not detect a clear pattern that demonstrates a phylogenetic association among non-recurrent or recurrent isolates. Thus, in concordance with a preceding hypothesis [42], SNVs that accumulate with repeated reactivations of HSV-2 from a latent state do not necessarily lead to sequence convergence. However, the amount of time virus coexists with the host may influence sequence convergence and the recurrence history of GenBank strains included in our phylogenetic study is unknown. Second, the phylogeny observed for clinical isolates is generally similar to the phylogenetic relationships described for the same clinical samples but using the complete HSV-2 genome [42–44]. For example, some clusters observed in our Us7-Us9 phylogeny (e.g. cluster I and VIII) have been previously described in other U.S. HSV-2 phylogenies based on the nearly complete genomes [42, 43]. Nevertheless, several exceptions were observed (e.g. sample 14 and 19), probably due to the limited genomic scope of a survey of the Us7-Us9 complex (3,768 nt) compared with the whole HSV-2 genome (~154,000 nt).

**Nucleotide variations shared between non-related strains**

Detailed examination of the nucleotide and amino acid sequences of the glycoprotein Us7-Us9 complex in 55 U.S. HSV-2 sequences revealed six nucleotide variations shared between strains
nested in different clusters (S1 Fig), four of which were non-synonymous (Fig 3). Polymorphisms in coding regions may allow a variant to emerge which could, for example, evade host immune surveillance or adapt to a new host’s genetic makeup. However, lack of homologous crystal structure models precluded interpretation of their significance. At least two evolutionary processes could explain the presence of identical nucleotide variations among non-related strains. The parallel nucleotide substitution theory has been previously invoked to explain analogous evolutionary events in diverse groups [45], and mutation-driven parallel evolution during viral adaptation [46]. However, random mutation leading to homoplasy is improbable based on the high number of identical mutations in non-related taxa observed in the small Us7-Us9 complex (3,768 nt). Alternatively, homologous recombination has been previously described as part of the evolution of many alphaherpesviruses [47], particularly within the HSV-2 genome [43, 44, 48, 49], and within and between HSV-2 glycoproteins and their HSV-1 counterparts [50]. Thus, the most likely explanation for the six nucleotide variations shared between non-related clusters (Fig 3 and S1 Fig) is recombination. Previous phylogenetic studies of HSV-2 have concluded that determining inter-strain phylogenies is difficult due to extensive recombination, leading to an underestimate of phylogenetic groupings [43, 48]. This recombination is implied by inconsistent phylogenetic signals across sequence alignments in Bootscan analysis, which suggests that HSV-2 strains observed are a genetic mosaic [43].

“Non-recurrent” isolates were defined as samples from subjects who became infected but did not have recurrent disease within the 20-month observation period post vaccine dose 2. Though these subjects have an apparently less severe disease course because first disease recurrence is likely to occur within the first year [51], they may not be strictly “non-recurrent” if they had been followed over a longer time period or if they had had subclinical reactivations. Only 8 individuals in this study who became infected with HSV-2 during the Trial had recurrent episodes of disease, so our sample size for analyzing sequence variations associated with recurrence is small. Additional vaccine trials may expand our dataset and allow a variant associated with recurrence to emerge.

Supporting information

S1 Fig. Phylogenetic reconstruction and nucleotide variants shared among different U.S. HSV-2 clusters. Nucleotide sequences in the SD90e reference strain correspond to Us7 (highlighted in green), Us8 (yellow), Us8A (orange) and Us9 (grey). In addition to the color coding, each gene segment is also labeled with a bracket in the bottom of the figure. Nucleotide sequences were ordered according to the Bayesian tree diagrammed on the left side of the figure. Blue and red accession numbers represent, respectively, non-recurrent and recurrent isolates (Table 2). A) Regions with variation between nucleotides 244 and 1910; B) regions with variation between nucleotides 1995 and 3759. Colored bands represent clusters supported by two different methods of analysis. The position of each nucleotide variation shared by non-related clusters is indicated above the reference strain (♦, non-synonymous and ◆, synonymous). The nucleotide positions at which multiple SNVs occur (♦) is also indicated. Bayesian posterior probabilities (≥80%) and maximum-parsimony bootstrap (≥65%) / maximum-likelihood bootstrap (≥65%) values appear above and below the branches, respectively. * High-passage laboratory strain.

S2 Fig. Bayesian Majority Rule consensus tree of HSV-2 based on the Us7-Us9 region (coding and non-coding sequences). The phylogeny of HSV-2 strains collected from diverse parts of the world (see color key and Table 2) with special emphasis on strains sampled in the U.S. (bold black font). Blue and red entries represent, respectively, U.S. non-recurrent and
recurrent HSV-2 isolates sequenced in this research. Bayesian posterior probabilities (≥80%) appear above the branches and Maximum-Parsimony bootstrap (≥65%) / Maximum-Likelihood bootstrap (≥65%) values appear below the branches. The eight different clusters from Fig 3 and S1 Fig are noted on the right side of the tree. A) Upper half of the phylogenetic tree; B) lower half of the tree.

Acknowledgments
The authors are grateful to Andreu Gazquez Casals for cell preparation.

Author Contributions

Conceptualization: Miguel A. Minaya, Lynda A. Morrison.

Data curation: Miguel A. Minaya.

Formal analysis: Kelsey L. Rowe, Miguel A. Minaya.

Funding acquisition: Robert B. Belshe, Lynda A. Morrison.

Investigation: Kelsey L. Rowe, Miguel A. Minaya.

Methodology: Miguel A. Minaya, Lynda A. Morrison.

Project administration: Lynda A. Morrison.

Resources: Robert B. Belshe, Lynda A. Morrison.

Supervision: Miguel A. Minaya, Lynda A. Morrison.

Validation: Miguel A. Minaya, Lynda A. Morrison.

Visualization: Kelsey L. Rowe, Miguel A. Minaya, Lynda A. Morrison.

Writing – original draft: Kelsey L. Rowe.

Writing – review & editing: Kelsey L. Rowe, Miguel A. Minaya.

References

1. Whitley R, Illiard J. Cercopithecine Herpes Virus 1 (B Virus). In: Knipe D, Howley P, Griffin D, Lamb R, Martin M, Roizman B, et al., editors. Fields Virology. II. Fifth ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. p. 2889–904.

2. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis. 2003; 30(10):797–800. Epub 2003/10/02. https://doi.org/10.1097/01.OLQ.0000092387.58746.C7 PMID: 14520181.

3. Beydoun HA, Dail J, Ugwu B, Boueiz A, Beydoun MA. Socio-demographic and behavioral correlates of herpes simplex virus type 1 and 2 infections and co-infections among adults in the USA. International Journal of Infectious Diseases. 2010; 14:e154–e60. https://doi.org/10.1016/j.ijid.2009.12.007. PMID: 20418142.

4. Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev. 2004; 17(1):1–13. Epub 2004/01/17. https://doi.org/10.1128/CMR.17.1.1-13.2004 PMID: 14726453; PubMed Central PMCID: PMCPMC321459.

5. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis. 2014; 209(3):325–33. Epub 2013/10/19. https://doi.org/10.1093/infdis/jit458 PMID: 24136792.

6. Le Doare K, Menson E, Patel D, Lim M, Lyall H, Herberg J. Fifteen minute consultation: Managing neonatal and childhood herpes encephalitis. Archives of disease in childhood—Education & practice edition. 2015; 100(2):58–63. https://doi.org/10.1136/archdischild-2014-306321 PMID: 25112286
7. Caviness AC. Neonatal Herpes Simplex Virus Infection. Clinical Pediatric Emergency Medicine. 2013; 14(2):135–45. https://doi.org/10.1016/j.cpem.2013.04.002.

8. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens. The Lancet. 2002; 359(9305):507–13. https://doi.org/10.1016/S0140-6736(02)07081-X.

9. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007; 370(9605):2127–37. Epub 2007/12/25. https://doi.org/10.1016/S0140-6736(07)61908-4 PMID: 18156035.

10. Bridge AD, Card JP, Enquist LW. Role of pseudorabies virus Us9, a type II membrane protein, in infection of tissue culture cells and the rat nervous system. J Virol. 2000; 74(2):834–45. Epub 2000/01/07. PMID: 10623746; PubMed Central PMCID: PMCPMC111604.

11. DuRaine G, Wisner TW, Howard P, Williams M, Johnson DC. Herpes Simplex Virus gE/gI and US9 Promote both Envelopment and Sorting of Virus Particles in the Cytoplasm of Neurons, Two Processes That Precede Anterograde Transport in Axons. J Virol. 2017; 91(11). Epub 2017/03/24. https://doi.org/10.1128/JVI.00050-17 PMID: 28331094; PubMed Central PMCID: PMCPMC5432863.

12. Awasthi S, Friedman HM. Molecular association of herpes simplex virus type 1 glycoprotein E with membrane protein Us9. Archives of Virology. 2016; 161(11):3203–13. https://doi.org/10.1007/s00705-016-3028-z PMID: 27568015.

13. Brandimarti R, Hill GS, Geiger JD, Meucci O. The lipid raft-dwelling protein US9 can be manipulated to target APP compartmentalization, APP processing, and neurodegenerative disease pathogenesis. Scientific Reports. 2017; 7(1):15103. https://doi.org/10.1038/s41598-017-15128-8 Brandimarti 2017. PMID: 29118375.

14. Lyman MG, Kemp CD, Taylor MP, Enquist LW. Comparison of the Pseudorabies Virus Us9 Protein with Homologs from Other Veterinary and Human Alphaherpesviruses. Journal of Virology. 2009; 83(14):6978–86. https://doi.org/10.1128/JVI.00598-09 PMID: 19420087.

15. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy Results of a Trial of a Herpes Simplex Vaccine. New England Journal of Medicine. 2012; 366(1):34–43. https://doi.org/10.1056/NEJMoa1103151 PMID: 22216840.

16. Lubinski J, Nagashunmugam T, Friedman HM. Viral interference with antibody and complement. Semin Cell Dev Biol. 1998; 9(3):329–37. Epub 1998/07/17. https://doi.org/10.1006/scdb.1998.0242 PMID: 9665870.

17. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, Cohen GH. Herpes virus fusion and entry: a story with many characters. Viruses. 2012; 4(5):800–32. Epub 2012/07/04. https://doi.org/10.3390/v4050800 PMID: 22754650; PubMed Central PMCID: PMCPMC3386629.

18. Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, et al. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A. 2003; 100(22):12889–904. Epub 2003/10/21. https://doi.org/10.1073/pnas.2131705100 PMID: 14566059; PubMed Central PMCID: PMCPMC240716.

19. Kato A, Ando T, Oda S, Watanabe M, Koyanagi N, Arii J, et al. Roles of Us8A and Its Phosphorylation Mediated by Us3 in Herpes Simplex Virus 1 Pathogenesis. J Virol. 2016; 90(12):5622–35. Epub 2016/04/01. https://doi.org/10.1128/JVI.00446-16 PMID: 27030266; PubMed Central PMCID: PMCPMC4886770.

20. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol Biol Evol. 2016; 33(7):1870–4. Epub 2016/03/24. https://doi.org/10.1093/molbev/msw054 PMID: 27040049.
26. Colgrove R, Diaz F, Newman R, Salf S, Shea T, Young S, et al. Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain. Virology. 2014;450-451:140–5. Epub 2014/02/02. https://doi.org/10.1016/j.virol.2014.07.007 PMID: 24503076; PubMed Central PMCID: PMCPMC395984.

27. Korber B. HIV Signature and Sequence Variation Analysis. In: Rodrigo AG, Learn GH, editors. Computational Analysis of HIV Molecular Sequences. Dordrecht, Netherlands: Kluwer Academic Publishers; 2000. p. 55–72.

28. Kryazhimskiy S, Plotkin JB. The population genetics of dN/dS. PLoS Genet. 2008; 4(12):e1000304. Epub 2008/12/17. https://doi.org/10.1371/journal.pgen.1000304 PMID: 19081788; PubMed Central PMCID: PMCPMC2596312.

29. Altekar G, Dwarkadas S, Huelsenbeck JP, Ronquist F. Parallel Metropolis coupled Markov chain Monte Carlo for Bayesian phylogenetic inference. Bioinformatics. 2004; 20(3):407–15. Epub 2004/02/13. https://doi.org/10.1093/bioinformatics/btg427 PMID: 14960467.

30. Ronquist F, Teslenko M, van der Mark P, Ayres DL, Darling A, Hohna S, et al. MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space. Syst Biol. 2012; 61(3):539–42. Epub 2012/02/24. https://doi.org/10.1093/sysbio/sys029 PMID: 22357727; PubMed Central PMCID: PMCPMC3329765.

31. Swoford DL. PAUP*: Phylogenetic analysis using parsimony (and other methods) 4.0.b10: Sinauer Associates, Sunderland, MA; 2003.

32. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol; 2010; 59(3):370–81. Epub 2010/06/09. https://doi.org/10.1093/sysbio/sys010 PMID: 20525638.

33. Schwarz G. Estimating the Dimension of a Model. The Institute of Mathematical Statistics. 1978:461–464.

34. Swofford DL. PAUP*: Phylogenetic analysis using parsimony (and other methods) 4.0.b10: Sinauer Associates, Sunderland, MA; 2003.

35. Minin V, Arle J, Lefort V, Anisimova M, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003; 52(5):696–704. Epub 2003/10/08. PMID: 14530136.

36. DeBry RW, Omland KE. A simulation study of reduced tree-search effort in bootstrap resampling analysis. Syst Biol. 2000; 49(1):171–89. Epub 2002/07/16. PMID: 12116479.

37. Snyder A, Policicova K, Johnson DC. Herpes simplex virus gE/gI and US9 proteins promote transport of both capsids and virion glycoproteins in neuronal axons. J Virol. 2008; 82(21):10613–24. Epub 2008/08/30. https://doi.org/10.1128/JVI.01241-08 PMID: 18753205; PubMed Central PMCID: PMCPMC2573198.

38. Diefenbach RJ, Davis A, Miranda-Saksena M, Fernandez MA, Kelly BJ, Jones CA, et al. The Basic Domain of Herpes Simplex Virus 1 pUS9 Recruits Kinesin-1 To Facilitate Egress from Neurons. J Virol. 2016; 90(4):2102–11. Epub 2015/12/15. https://doi.org/10.1128/JVI.03041-15 PMID: 26656703; PubMed Central PMCID: PMCPMC4733978.

39. Minaya MA, Jensen TL, Goll JB, Korom M, Datla SH, Beishe RB, et al. Molecular Evolution of Herpes Simplex Virus 2 Complete Genomes: Comparison between Primary and Recurrent Infections. J Virol. 2017; 91(23). Epub 2017/09/22. https://doi.org/10.1128/jvi.00942-17 PMID: 28931680; PubMed Central PMCID: PMCPMC5668715.

40. Kolb AW, Larsen IV, Cuenier JA, Brandt CR. Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains. J Virol. 2015; 89(12):6427–34. Epub 2015/04/10. https://doi.org/10.1128/JVI.00416-15 PMID: 25855744; PubMed Central PMCID: PMCPMC4474301.

41. Newman RM, Lamers SL, Weiner B, Ray SC, Colgrove RC, Diaz F, et al. Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol. 2015; 89(16):8219–32. Epub 2015/05/29. https://doi.org/10.1128/JVI.01303-15 PMID: 26016166; PubMed Central PMCID: PMCPMC4524243.

42. Wood TE, Burks JM, Riceberg LH. Parallel genotypic adaptation: when evolution repeats itself. Genetics. 2008; 123(1–2):157–70. PMID: 18881688; PubMed Central PMCID: PMCPMC2449217.

43. Lackman AM, McGee LW, Morrison AJ, Pierce J, Anisman J, Hamilton H, et al. Mutation-Driven Parallel Evolution during Viral Adaptation. Molecular Biology and Evolution. 2017; 34(12):3243–53. https://doi.org/10.1093/molbev/msx257 PMID: 29029274
47. Loncoman CA, Vaz PK, Coppo MJ, Hartley CA, Morera FJ, Browning GF, et al. Natural recombination in alphaherpesviruses: Insights into viral evolution through full genome sequencing and sequence analysis. Infect Genet Evol. 2017; 49:174–85. Epub 2016/12/27. https://doi.org/10.1016/j.meegid.2016.12.022 PMID: 28017915.

48. Norberg P, Kasubi MJ, Haarr L, Bergstrom T, Liljeqvist JA. Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol. 2007; 81(23):13158–67. Epub 2007/09/21. https://doi.org/10.1128/JVI.01310-07 PMID: 17881457; PubMed Central PMCID: PMCPMC2169075.

49. Koelle DM, Norberg P, Fitzgibbon MP, Russell RM, Greninger AL, Huang ML, et al. Worldwide circulation of HSV-2 x HSV-1 recombinant strains. Sci Rep. 2017; 7:44084. Epub 2017/03/14. https://doi.org/10.1038/srep44084 PMID: 28287142; PubMed Central PMCID: PMCPMC5347006.

50. Lamers SL, Newman RM, Laeyendecker O, Tobian AA, Colgrove RC, Ray SC, et al. Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. J Virol. 2015; 89(16):8206–18. Epub 2015/05/29. https://doi.org/10.1128/JVI.01302-15 PMID: 26018161; PubMed Central PMCID: PMCPMC4524236.

51. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994; 121(11):847–54. Epub 1994/12/01. PMID: 7978697.